1. Home
  2. PHVS

as of 03-12-2026 3:59pm EST

$26.36
$1.07
-3.90%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Founded: 2015 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 1.8B IPO Year: 2020
Target Price: $40.70 AVG Volume (30 days): 99.0K
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $11.51 - $29.80 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: